相关实验视频

Updated: Jan 7, 2026

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

针对乳腺癌的沙衍生物的向抗癌潜力:合成,分子对接,动力学模拟和ERBB3受体体体外评估

Jianxing Xu¹, Dongwei Zhu², Kanagaraj Rajalakshmi²

¹Department of Radiology, Wujin Hospital Affiliated with Jiangsu University, Changzhou 213002, China; Department of Radiology, The Wujin Clinical college of Xuzhou Medical University, Changzhou 213002, China.

Computational biology and chemistry

|December 30, 2025

概括

一种新型化合物PS13有效地阻断了ERBB3受体,显示了乳腺癌治疗的前景. 它的稳定配方和强大的抗癌活性在体外表明显著的临床前潜力.

科学领域:

药用化学医学化学
分子生物学分子生物学
纳米技术纳米技术

背景情况:

ERBB3受体与乳腺癌的发展有关.
准ERBB3为乳腺癌提供了一个潜在的治疗策略.

研究的目的:

合成和表征一种新型的氧沙衍生物PS13,旨在抑制ERBB3受体.
评估PS13的结合亲和力,稳定性,药物动力学特性和体外抗癌疗效.

主要方法:

合成和结构验证PS13使用IR,NMR,MS和元素分析.
分子对接和动力学模拟以评估ERBB3结合和复合稳定性.
对于药物动力学和电子性质的ADMET分析和密度功能理论分析.
加载PS13的固体脂质纳米颗粒 (SLN) 的配方和封装和释放配置文件的评估.
在体外细胞毒性测定 (MTT) 在MCF-7细胞和形态学研究.

主要成果:

PS13对ERBB3 (-9.5 kcal/mol) 显示出强烈的结合亲和力,并形成稳定的联体受体复合体.
在分析预测了有利的类似药物的特性和良好的代谢稳定性.
PS13-SLNs表现出高封装效率 (81%) 和受控释放.
试验室研究显示,对MCF-7细胞的剂量依赖性细胞毒性 (IC50 = 60.27μg/mL) 和诱导的亡.

结论:

由于其高ERBB3结合亲和力和强大的体外抗癌活性,PS13是乳腺癌治疗的有前途的化合物.
稳定的SLN配方增强了药物输送和受控释放.
PS13需要进一步的临床前开发来治疗乳腺癌.

关键词:

它具有抗癌活性.乳腺癌是什么? 乳腺癌是什么在ERBB3受体中,ERBB3受体是分子对接是分子对接.氧沙的衍生品氧沙衍生品

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...